‘US Consumption of Alcoholic Beverages Is at Historic Lows’: Heineken Hires GLP-1 Pitchwoman to Sell Beer
US alcohol consumption is at historic lows, according to a Gallup poll. Molson Coors (TAP) and Boston Beer (SAM) reported declines in shipments and depletions, respectively. Heineken's CEO called the impact of GLP-1 drugs on drinking habits 'inconclusive.' Molson Coors expects an 11-15% EPS decline in 2026 and is investing in beyond-beer products.
How this was made
The 30-second read
Why it matters
Earnings disappointments and sector contraction suggest short‑term weakness for US beer stocks.
Market read
Both SAM and TAP face immediate downside risk due to fresh earnings misses amid a sector downturn.
What to watch
Advertising spend increase at Boston Beer may mitigate the decline over the longer term.
Background
The article discusses Q2 earnings misses for two major US‑listed brewers and a GLP‑1 partnership aimed at reversing declining alcohol consumption.
Ticker impact
Boston Beer reported Q2 FY2026 adjusted EPS of $3.65, missing consensus by 24% and depletions down 6%.
Potential downside of 3‑5% over the next few days.
The miss is material and fresh; investors may cut exposure.
Molson Coors missed Q2 EPS by 24% and US shipments fell 7% as the beer industry contracted 4% in the quarter.
Expect a 2‑4% decline in the near term.
New earnings data with clear downside guidance.
Market effects
The broader beer sector shows a 4% contraction, pressuring peers.
US beer consumption at historic lows may affect domestic brewers.
International brewers with US exposure could see similar pressure.
Counterpoint
Heineken's GLP‑1 ambassador could spark a rebound if weight‑loss drugs boost occasional drinking.
Key entities
- CompanyBoston Beer
Maker of Samuel Adams, reported Q2 EPS miss.
- CompanyMolson Coors
Brewer with TAP ticker, reported Q2 EPS miss and shipment decline.
